Loading
A phase 2 trial of Bevacizumab, Sintilimab in hepatocellular carcinoma, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT06558227 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 90 participants planned, started 2024-10-24 and due to reach its primary completion in 2026-09. Interventions recorded: ZG005 for Injection, Bevacizumab, Sintilimab, Bevacizumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Suzhou Zelgen Biopharmaceuticals, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Sintilimab, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Sintilimab, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/